Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Vanessa L Schumacher und 27 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland. Hauptthemen laut MEDLINE: B-Lymphocytes, Antigens, CD20, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Abstract (Originalsprache)
Background
The blood–brain barrier (BBB) presents a major challenge for the development of monoclonal antibody (mAb)‐based therapies for brain disorders. To improve the likelihood of success of such therapies, Roche Brainshuttle technology utilizes a single anti‐transferrin receptor 1 (TfR1)‐antigen‐binding antibody fragment linked to a therapeutic antibody, allowing engagement with TfR1 to transport the therapeutic antibody into the brain via receptor‐mediated transcytosis.
Methods
We compared Fc‐silenced and Fc‐competent variants of the Brainshuttle and the parental (non‐shuttled) type II CD20 mAb, obinutuzumab in in vitro and in vivo (mouse and cynomolgus macaque) models. Endpoints assessed included B cell binding, B cell killing, tolerability, and ability to cross the BBB.
Results
The Fc‐silenced Brainshuttle construct showed a superior safety profile compared with the Fc‐competent construct while maintaining the ability to cross the BBB and to deplete B cells in head‐to‐head comparisons in human and mouse in vitro and in mouse and cynomolgus macaque in vivo models.
Conclusion
Together, our data provide a path forward for the future development of safe and efficacious brain‐targeted B‐cell‐depleting therapies. Key points The BBB hinders mAb‐based brain disorder therapies A brain‐targeted B‐cell‐depleting mAb for MS that efficiently crosses the BBB via hTfR1 was developed using Brainshuttle ™ technology (1a and 1b) The Brainshuttle ™ ‐CD20 mAb was well tolerated (2a and 2b) and displayed B‐cell‐killing properties (1c), paving the way for future development and clinical translation of TfR1‐targetingtherapies for increased brain penetration
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
- Roche Pharma Research and Early Development, Roche Innovation Center, Zurich, Switzerland.
- Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany.
- Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zürich, Switzerland.
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
- Personalized Healthcare Safety, Product Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Förderung
- Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Zitieren
APA
Schumacher, V. L., Pichereau, S., Bessa, J., Bachl, J., Herter, S., Weber, F. C., Auer, J., Kipar, A., Winter, M., Stirn, M., Otteneder, M. B., Brady, K., Eichinger-Chapelon, A., Roth, A., Stokar-Regenscheit, N., Clemann, N., Seger, S., Senn, C., Hönig, J., …, & Urich, E. (2025). Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70178
Vancouver
Schumacher VL, Pichereau S, Bessa J, Bachl J, Herter S, Weber FC, et al. Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70178
BibTeX
@article{Schumacher2025,
author = {Schumacher, Vanessa L and Pichereau, Solen and Bessa, Juliana and Bachl, Juergen and Herter, Sylvia and Weber, Felix C and Auer, Johannes and Kipar, Anja and Winter, Michael and Stirn, Martina and Otteneder, Michael B and Brady, Kevin and Eichinger-Chapelon, Anne and Roth, Adrian and Stokar-Regenscheit, Nadine and Clemann, Nicole and Seger, Shanon and Senn, Claudia and Hönig, Juliane and Jany, Cordula and Lenarda, Elisa Di and Tissot, Alain C and Klein, Christian and von Büdingen, H-Christian and Mader, Robert and Ullah, Mohammed and Janssen, Niels and Urich, Eduard},
title = {Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70178}
}
EUVIMED